Rachelle Suzanne Jacques - Net Worth and Insider Trading

Rachelle Suzanne Jacques Net Worth

The estimated net worth of Rachelle Suzanne Jacques is at least $88,633 dollars as of 2024-06-10. Rachelle Suzanne Jacques is the Director of uniQure NV and owns about 16,629 shares of uniQure NV (QURE) stock worth over $88,633. Details can be seen in Rachelle Suzanne Jacques's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Rachelle Suzanne Jacques has not made any transactions after 2023-06-16 and currently still holds the listed stock(s).

Transaction Summary of Rachelle Suzanne Jacques

Rachelle Suzanne Jacques Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Rachelle Suzanne Jacques owns 3 companies in total, including Viela Bio Inc (VIE) , Corbus Pharmaceuticals Holdings Inc (CRBP) , and uniQure NV (QURE) .

Click here to see the complete history of Rachelle Suzanne Jacques’s form 4 insider trades.

Insider Ownership Summary of Rachelle Suzanne Jacques

Ticker	Comapny	Transaction Date	Type of Owner
VIE	Viela Bio Inc	2020-06-19	director
CRBP	Corbus Pharmaceuticals Holdings Inc	2019-04-05	director
QURE	uniQure NV	2023-06-16	director

Rachelle Suzanne Jacques Latest Holdings Summary

Rachelle Suzanne Jacques currently owns a total of 1 stock. Rachelle Suzanne Jacques owns 16,629 shares of uniQure NV (QURE) as of June 16, 2023, with a value of $88,633.

Latest Holdings of Rachelle Suzanne Jacques

Ticker	Comapny	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
QURE	uniQure NV	2023-06-16	16,629	5.33	88,633

Holding Weightings of Rachelle Suzanne Jacques

Rachelle Suzanne Jacques Form 4 Trading Tracker

According to the SEC Form 4 filings, Rachelle Suzanne Jacques has made a total of 1 transactions in uniQure NV (QURE) over the past 5 years, including 0 buys and 1 sells. The most-recent trade in uniQure NV is the sale of 2,301 shares on June 16, 2023, which brought Rachelle Suzanne Jacques around $43,167.

Insider Trading History of Rachelle Suzanne Jacques

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Rachelle Suzanne Jacques Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Rachelle Suzanne Jacques Ownership Network

Ownership Network List of Rachelle Suzanne Jacques

No Data

Ownership Network Relation of Rachelle Suzanne Jacques

Rachelle Suzanne Jacques Owned Company Details

What does Viela Bio Inc do?

Who are the key executives at Viela Bio Inc?

Rachelle Suzanne Jacques is the director of Viela Bio Inc. Other key executives at Viela Bio Inc include 10 percent owner Boyu Capital General Partner III, Ltd. , 10 percent owner Boyu Capital Group Holdings Ltd. , and 10 percent owner Boyu Capital Investment Management Ltd .

Viela Bio Inc (VIE) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Viela Bio Inc (VIE) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Viela Bio Inc (VIE) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Viela Bio Inc (VIE)'s detailed insider trading history can be found in Insider Trading Tracker table.

Viela Bio Inc Insider Transactions

No Available Data

What does Corbus Pharmaceuticals Holdings Inc do?

Who are the key executives at Corbus Pharmaceuticals Holdings Inc?

Rachelle Suzanne Jacques is the director of Corbus Pharmaceuticals Holdings Inc. Other key executives at Corbus Pharmaceuticals Holdings Inc include Chief Financial Officer Sean F. Moran , director & Chief Executive Officer Yuval Cohen , and Chief Commercial Officer Craig Stuart Millian .

Corbus Pharmaceuticals Holdings Inc (CRBP) Insider Trades Summary

Over the past 18 months, Rachelle Suzanne Jacques made no insider transaction in Corbus Pharmaceuticals Holdings Inc (CRBP). Other recent insider transactions involving Corbus Pharmaceuticals Holdings Inc (CRBP) include a net purchase of 1,032,632 shares made by Cormorant Global Healthcare Master Fund, Lp , and a net purchase of 550,000 shares made by Cormorant Asset Management, Lp .

In summary, during the past 3 months, insiders sold 0 shares of Corbus Pharmaceuticals Holdings Inc (CRBP) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Corbus Pharmaceuticals Holdings Inc (CRBP) were sold and 1,582,632 shares were bought by its insiders, resulting in a net purchase of 1,582,632 shares.

Corbus Pharmaceuticals Holdings Inc (CRBP)'s detailed insider trading history can be found in Insider Trading Tracker table.

Corbus Pharmaceuticals Holdings Inc Insider Transactions

No Available Data

What does uniQure NV do?

Who are the key executives at uniQure NV?

Rachelle Suzanne Jacques is the director of uniQure NV. Other key executives at uniQure NV include director & CEO & Managing Director Matthew C Kapusta , Chief Financial Officer Christian Klemt , and Chief Operating Officer Pierre Caloz .

uniQure NV (QURE) Insider Trades Summary

Over the past 18 months, Rachelle Suzanne Jacques made 1 insider transaction in uniQure NV (QURE) with a net sale of 2,301. Other recent insider transactions involving uniQure NV (QURE) include a net sale of 28,482 shares made by Pierre Caloz , a net sale of 18,479 shares made by Christian Klemt , and a net sale of 15,075 shares made by Paula Soteropoulos .

In summary, during the past 3 months, insiders sold 0 shares of uniQure NV (QURE) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 117,072 shares of uniQure NV (QURE) were sold and 0 shares were bought by its insiders, resulting in a net sale of 117,072 shares.

uniQure NV (QURE)'s detailed insider trading history can be found in Insider Trading Tracker table.

uniQure NV Insider Transactions

No Available Data

Rachelle Suzanne Jacques Mailing Address

Above is the net worth, insider trading, and ownership report for Rachelle Suzanne Jacques. You might contact Rachelle Suzanne Jacques via mailing address: C/o Corbus Pharmaceuticals Holdings, Inc, 100 River Ridge Drive, Norwood Ma 02062.

Discussions on Rachelle Suzanne Jacques

No discussions yet.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.